` 2162 (KeyMed Biosciences Inc) vs Hang Seng (Hong Kong) Comparison - Alpha Spread

K
2162
vs
H
Hang Seng (Hong Kong)

Over the past 12 months, KeyMed Biosciences Inc has outperformed Hang Seng (Hong Kong), delivering a return of +36% compared to the Hang Seng (Hong Kong)'s +27% growth.

Stocks Performance
2162 vs Hang Seng (Hong Kong)

Loading
2162
Hang Seng (Hong Kong)
Add Stock
www.alphaspread.com

Performance Gap
2162 vs Hang Seng (Hong Kong)

Loading
2162
Hang Seng (Hong Kong)
Difference
www.alphaspread.com

Performance By Year
2162 vs Hang Seng (Hong Kong)

Loading
2162
Hang Seng (Hong Kong)
Add Stock

Competitors Performance
KeyMed Biosciences Inc vs Peers

Hang Seng (Hong Kong)
2162
ABBV
AMGN
GILD
VRTX
Add Stock

KeyMed Biosciences Inc
Glance View

Market Cap
17.9B HKD
Industry
Biotechnology

In the bustling city of Chengdu, China, amid the rise of modern medical innovation, KeyMed Biosciences Inc. has emerged as a prominent player in the biotechnology sector. Established by a team of experienced scientists and industry veterans, the company focuses on the discovery and development of novel biologic therapies aimed at addressing critical unmet medical needs, particularly within the oncology and autoimmune disease spaces. With its proprietary technology platforms, KeyMed drives its research and development by leveraging extensive capabilities in monoclonal antibody discovery and engineering. This approach allows the company to create innovative products that potentially offer superior efficacy and safety profiles compared to existing treatments, thus underpinning its mission to contribute significantly to global healthcare advancements. KeyMed Biosciences operates on a business model primarily centered around product development pipelines, strategic partnerships, and licensing agreements. The company's revenue streams are chiefly generated from licensing out its proprietary drug candidates and technologies to major pharmaceutical companies, who seek late-stage and commercialized assets. These collaborations not only provide the financial means necessary to fuel ongoing R&D but also facilitate accelerated development timelines and expand the reach of their therapeutic innovations. Furthermore, as these candidates progress through clinical trials and receive regulatory approvals, KeyMed stands to gain from milestone payments and, eventually, a share of sales revenues. This symbiotic relationship between cutting-edge research and astute financial strategies defines KeyMed's path forward in a competitive industry landscape.

Intrinsic Value
57.91 HKD
Overvaluation 4%
Intrinsic Value
Price
K
Back to Top